Vanderbilt Vaccine Center Archive
-
September 4, 2019
Partnership to help bring Zika virus therapy to clinic
Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. -
July 9, 2019
Vanderbilt vaccine pioneer James Crowe honored with major science prize
James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses. -
June 14, 2019
New method tested to block chikungunya infection
Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. -
June 6, 2019
VUMC joins international effort to speed vaccine development
VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections. -
May 16, 2019
Flu’s “hidden target” may lead to universal vaccine: study
Researchers at Vanderbilt University Medical Center and the Scripps Research Institute have discovered a “hidden target” on the surface of the hypervariable influenza A virus that could lead to better ways to prevent and treat the flu. -
April 11, 2019
VUMC-led team ‘sprints’ to develop Zika virus treatment
In January scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis were given an audacious goal to develop — in 90 days — a protective antibody-based treatment that potentially will stop the spread of the Zika virus. -
March 25, 2019
VUMC joins effort to stop spread of two deadly viruses
Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.